Get in touch

Safety Profile

832 ≥12 years old, randomised into 4, 14 day placebo controlled SAR trials.

Price et al. Short and long-term safety of MP29-02*: A new therapy (MP29-02*) effectively targets the entire seasonal
allergic rhinitis symptom complex.
Abstract presented at the Symposium on Experimental Rhinology and Immunology of the Nose (SERIN), Leuven (Belgium) 21-23 March 2013.